ProductDescription
VX-702isanorally-available,aminopyridine-based,ATP-competitiveinhibitorofp38MAPKwithaKdof3.7nMand17nMat10uMforp38aandp38b,respectively.[1]InanexvivobloodassayprimedwithLPS<VX-702dose-dependentlyinhibitedtheproductionofIL-6,IL-1b,TNFaatIC50of59,122,and99ng/mL,respectively.[2]VX-702wasfoundtobeequivalenttoprednisoloneandmethotrexateinamousecollagen-inducedarthritismodel.
ClinicalefficacymodelsplustransientsuppressionofinflammationbioMarkerssuggestthatp38MAPKinhibitionbyagentssuchasVX-702maynotbeaviableapproachtothetreatmentofchronicinflammationinRA.[3]
Technicalinformation:
| ChemicalFormula: | C19H12F4N4O2 | |
| CAS#: | 479543-46-9 | |
| MolecularWeight: | 404.32 | |
| Purity: | >98% | |
| Appearance: | White | |
| ChemicalName: | 1-(5-carbamoyl-6-(2,4-difluorophenyl)pyridin-2-yl)-1-(2,6-difluorophenyl)urea | |
| Solubility: | Upto100mMinDMSO | |
| Synonyms: | VX-702,VX702 |
ShippingCondition:Theproductisshippedinaglassvialatambienttemperature.
Storagecondition:Forlongershelflife,storesolidpowderat4oCdesiccated,orstoreDMSOsolutionat-20oC.
Reference:
| 1. | Goldsteinetal.,Selectivep38alphainhibitorsclinicallyevaluatedforthetreatmentofchronicinflammatorydisorders.J.Med.Chem.2010,53,2345-2353.PubmedID:19950901 |
| 2. | Ding,C.,Drugevaluation:VX-702,aMAPkinaseinhibitorforrheumatoidarthritisandacutecoronarysyndrome.Curr.Opin.Invest.Drugs,2006,7(11),1020-1025.PubmedID:17117592 |
| 3. | Damjanovetal.,Efficacy,pharmacodynamics,andsafetyofVX-702,anovelp38MAPKinhibitor,inrheumatoidarthritis:resultsoftworandomized,double-blind,placebo-controlledclinicalstudies.ArthritisRheum.,2009,60(5),1232-1241.PubmedID:19404957 |
Cellagen的ChamQ SYBR qPCR预混液（无ROX）| Q321产品描述ChamQSYBR®qPCR预混液（Vazyme，＃Q321）由香槟Taq DNA聚合酶（Vazyme，＃P122）通过抗体修饰的热启动激活技术保护，是专为基于SYBR Green I的定量PCR（qPCR）设计的。ChamQSYBR®qPCR Master Mix的优化缓冲液系统中的独特因素（即促进特异性的Exactor）大大提高了其灵敏度和特异性。该混合物以2倍反应浓度制备，可直接用于鲁棒性低模板qPCR，具有高灵敏度，特异性和可靠性。优点特异性+敏感性的最佳组合。独特的抗体修饰的热启动taq，具有独特的特异性促进因子。Mg2 +和染料的最佳浓度。
